Clinical-stage pharmaceutical company Spinogenix Inc announced on Monday that it has received approval from the International Nonproprietary Names (INN) Expert Committee of the World Health Organization for 'tazbentetol' as the non-proprietary name of the company's synaptic regenerative therapy, SPG302.

Tazbentetol is an oral investigational therapy being developed to restore synaptic function in neurodegenerative and psychiatric conditions including Alzheimer's disease, ALS and schizophrenia. According to Spinogenix, the unique synaptic regenerative activity is positioned as a first-in-class therapeutic with the potential to reverse declines in cognitive, motor, respiratory and sensory function.

Dr. Stella Sarraf, CEO and founder of Spinogenix, said: "With the planned announcement of topline results for our Phase 2a study in Alzheimer's disease at CTAD and in ALS at MNDA conferences this week, and upcoming completion of enrolment for our ongoing Phase 2 clinical trial in schizophrenia, receiving this INN marks another important step in the advancement of tazbentetol as a potential restorative therapeutic for patients seeking new treatments."